Contact
searchSearch
HMP Global
Login

Podcasts

Podcasts
Case Files: Axatilimab Use in a Patient With Chronic Graft-Versus-Host-Disease 
09/16/2025
Benjamin Watkins, MD
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using...
09/16/2025
Oncology
Podcasts
Navigating Second-Line Decisions: Real-World Management of Chronic Graft-Versus-Host Disease (GVHD)
09/16/2025
Shernan Holtan, MD
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results...
09/16/2025
Oncology
Podcasts
From Steroids to Second-Line Therapy—What Drives the Move? 
09/16/2025
Betty Hamilton, MD
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what...
09/16/2025
Oncology
Podcasts
Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment 
09/16/2025
Yi-Bin Chen, MD
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating...
09/16/2025
Oncology
Podcasts
Podcast: Selecting Second-Line Therapy for Relapsing/Remitting Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the...
05/13/2025
Oncology
Podcasts
Podcast: Targeted Therapies for Relapsing/Remitting Pediatric Low-Grade Glioma (R/R pLGG)
05/13/2025
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the...
05/13/2025
Oncology
Dr Hwang
Podcasts
Podcast: Oncogenic Drivers of Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the...
05/13/2025
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
Advances in Genetic Testing for Patients With Gastrointestinal Cancers
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use